Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop
- PMID: 19452263
- DOI: 10.1007/s10545-009-1126-8
Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop
Abstract
Published data on treatment of fatty acid oxidation defects are scarce. Treatment recommendations have been developed on the basis of observations in 75 patients with long-chain fatty acid oxidation defects from 18 metabolic centres in Central Europe. Recommendations are based on expert practice and are suggested to be the basis for further multicentre prospective studies and the development of approved treatment guidelines. Considering that disease complications and prognosis differ between different disorders of long-chain fatty acid oxidation and also depend on the severity of the underlying enzyme deficiency, treatment recommendations have to be disease-specific and depend on individual disease severity. Disorders of the mitochondrial trifunctional protein are associated with the most severe clinical picture and require a strict fat-reduced and fat-modified (medium-chain triglyceride-supplemented) diet. Many patients still suffer acute life-threatening events or long-term neuropathic symptoms despite adequate treatment, and newborn screening has not significantly changed the prognosis for these severe phenotypes. Very long-chain acyl-CoA dehydrogenase deficiency recognized in neonatal screening, in contrast, frequently has a less severe disease course and dietary restrictions in many patients may be loosened. On the basis of the collected data, recommendations are given with regard to the fat and carbohydrate content of the diet, the maximal length of fasting periods and the use of l-carnitine in long-chain fatty acid oxidation defects.
Similar articles
-
Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop.J Inherit Metab Dis. 2009 Aug;32(4):488-97. doi: 10.1007/s10545-009-1125-9. Epub 2009 Apr 29. J Inherit Metab Dis. 2009. PMID: 19399638
-
Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians.J Inherit Metab Dis. 2012 Jan;35(1):115-23. doi: 10.1007/s10545-011-9352-2. Epub 2011 Jun 1. J Inherit Metab Dis. 2012. PMID: 21630065
-
Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.Eur J Pediatr. 2019 Mar;178(3):387-394. doi: 10.1007/s00431-018-03315-2. Epub 2019 Jan 7. Eur J Pediatr. 2019. PMID: 30617651
-
Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.J Hum Genet. 2019 Feb;64(2):73-85. doi: 10.1038/s10038-018-0527-7. Epub 2018 Nov 6. J Hum Genet. 2019. PMID: 30401918 Review.
-
Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.J Inherit Metab Dis. 2010 Oct;33(5):527-32. doi: 10.1007/s10545-010-9090-x. Epub 2010 May 7. J Inherit Metab Dis. 2010. PMID: 20449660 Review.
Cited by
-
Fatty Acid oxidation disorders in a chinese population in taiwan.JIMD Rep. 2013;11:165-72. doi: 10.1007/8904_2013_236. Epub 2013 May 23. JIMD Rep. 2013. PMID: 23700290 Free PMC article.
-
Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.J Inherit Metab Dis. 2021 Jan;44(1):253-263. doi: 10.1002/jimd.12313. Epub 2020 Sep 14. J Inherit Metab Dis. 2021. PMID: 32885845 Free PMC article. Clinical Trial.
-
Metabolomic analyses of plasma reveals new insights into asphyxia and resuscitation in pigs.PLoS One. 2010 Mar 9;5(3):e9606. doi: 10.1371/journal.pone.0009606. PLoS One. 2010. PMID: 20231903 Free PMC article.
-
Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder.Am J Physiol Endocrinol Metab. 2013 Nov 15;305(10):E1299-308. doi: 10.1152/ajpendo.00225.2013. Epub 2013 Sep 24. Am J Physiol Endocrinol Metab. 2013. PMID: 24064340 Free PMC article.
-
Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts.Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H813-23. doi: 10.1152/ajpheart.01275.2010. Epub 2011 Jun 17. Am J Physiol Heart Circ Physiol. 2011. PMID: 21685264 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical